Symbols / PLUR $3.34 +1.64%
PLUR Chart
About
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 33.57M |
| Enterprise Value | 60.88M | Income | -26.14M | Sales | 1.34M |
| Book/sh | -1.46 | Cash/sh | 1.24 | Dividend Yield | — |
| Payout | 0.00% | Employees | 127 | IPO | — |
| P/E | — | Forward P/E | -1.76 | PEG | — |
| P/S | 25.07 | P/B | -2.28 | P/C | — |
| EV/EBITDA | -2.49 | EV/Sales | 45.47 | Quick Ratio | 0.39 |
| Current Ratio | 0.43 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.31 | EPS next Y | -1.90 | EPS Growth | — |
| Revenue Growth | 7.00% | Earnings | 2025-11-12 16:00 | ROA | -50.60% |
| ROE | — | ROIC | — | Gross Margin | 40.63% |
| Oper. Margin | -32.86% | Profit Margin | 0.00% | Shs Outstand | 10.05M |
| Shs Float | 4.53M | Short Float | 0.76% | Short Ratio | 2.51 |
| Short Interest | — | 52W High | 7.13 | 52W Low | 2.82 |
| Beta | 0.73 | Avg Volume | 15.54K | Volume | 8.17K |
| Target Price | $12.00 | Recom | None | Prev Close | $3.29 |
| Price | $3.34 | Change | 1.64% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$12.00
Mean price target
2. Current target
$3.34
Latest analyst target
3. DCF / Fair value
$-25.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.34
Low
$12.00
High
$12.00
Mean
$12.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-06-02 | init | Alliance Global Partners | — → Buy | $12 |
- Plurilock to Boost Defense and Cybersecurity Profile with Spring 2026 Conference Push - TipRanks ue, 17 Mar 2026 12
- Inside the push to turn human placentas into collagen for new therapies - Stock Titan hu, 22 Jan 2026 08
- Plurilock to Bolster Cyber Defense Profile With Spring 2026 Conference Push - TipRanks ue, 17 Mar 2026 12
- Pluri Regains Nasdaq Compliance, Restoring Listing Stability - The Globe and Mail ue, 03 Mar 2026 08
- Plurilock Security Inc.'s (CVE:PLUR) Shares Lagging The Industry But So Is The Business - simplywall.st ue, 16 Dec 2025 08
- Pluri (NASDAQ: PLUR) regains key Nasdaq listing standard compliance - Stock Titan Mon, 02 Mar 2026 08
- Insider Stock Purchases: November 20, 2025 | NEXT Stock News - Quiver Quantitative hu, 20 Nov 2025 08
- PLUR Forecast — Price Prediction for 2026. Should I Buy PLUR? - Intellectia AI hu, 29 May 2025 07
- Pluri (NASDAQ: PLUR) names Weinstein chair, adds $2.5M private placement - Stock Titan ue, 09 Dec 2025 08
- symbol__ Stock Quote Price and Forecast - CNN Sun, 03 Mar 2024 05
- New cell-free therapy for fibrotic diseases clears key manufacturing step - Stock Titan Mon, 22 Dec 2025 08
- Plurilock Targets Canadian Defense Cyber Boom as Critical Services Surge - TipRanks ue, 10 Mar 2026 12
- Pluri (NASDAQ: PLUR) teams with Miss Universe Skincare; Cellav exosome line H1 2026 - Stock Titan ue, 11 Nov 2025 08
- Pluri Faces Nasdaq Noncompliance Notice, Evaluating Listing Options - TipRanks hu, 22 Jan 2026 08
- Pluri Grants RSUs to Executives and Board Members - TipRanks ue, 09 Dec 2025 21
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 625000 | 1956250 | — | Stock Award(Grant) at price 3.13 per share. | MANIEU ALEXANDRE WEINSTEIN | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-08 00:00:00 | I |
| 1 | 6588 | — | — | Stock Award(Grant) at price 0.00 per share. | YANAY YAKY | Chief Executive Officer | — | 2025-12-04 00:00:00 | D |
| 2 | 699 | — | — | Stock Award(Grant) at price 0.00 per share. | SHEMESH-RASMUSSEN MAITAL | Director | — | 2025-12-04 00:00:00 | D |
| 3 | 653 | — | — | Stock Award(Grant) at price 0.00 per share. | LEVI RAMI AVRAHAM | Director | — | 2025-12-04 00:00:00 | D |
| 4 | 519 | — | — | Stock Award(Grant) at price 0.00 per share. | MANIEU ALEXANDRE WEINSTEIN | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-04 00:00:00 | D |
| 5 | 3660 | — | — | Stock Award(Grant) at price 0.00 per share. | ZALTS LIAT | Chief Financial Officer | — | 2025-12-04 00:00:00 | D |
| 6 | 668 | — | — | Stock Award(Grant) at price 0.00 per share. | AJCHENBAUM EITAN | Director | — | 2025-12-04 00:00:00 | D |
| 7 | 346 | — | — | Stock Award(Grant) at price 0.00 per share. | ABERMAN ZALMAN | Director | — | 2025-12-04 00:00:00 | D |
| 8 | 11685 | — | — | Stock Award(Grant) at price 0.00 per share. | AJCHENBAUM EITAN | Director | — | 2025-11-12 00:00:00 | D |
| 9 | 1002169 | 100 | — | Conversion of Exercise of derivative security at price 0.00 per share. | MANIEU ALEXANDRE WEINSTEIN | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-29 00:00:00 | I |
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -290.26 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -20.72M | -20.50M | -25.82M | -39.98M |
| TotalUnusualItems | -1.35M | 274.00K | -1.87M | 550.00K |
| TotalUnusualItemsExcludingGoodwill | -1.35M | 274.00K | -1.87M | 550.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -22.58M | -20.89M | -28.32M | -41.24M |
| ReconciledDepreciation | 316.00K | 253.00K | 362.00K | 1.05M |
| ReconciledCostOfRevenue | 682.00K | 4.00K | 9.00K | 0.00 |
| EBITDA | -22.07M | -20.23M | -27.68M | -39.43M |
| EBIT | -22.38M | -20.48M | -28.04M | -40.49M |
| NetInterestIncome | 271.00K | 540.00K | 225.00K | -331.00K |
| InterestExpense | 873.00K | 866.00K | 843.00K | 887.00K |
| InterestIncome | 1.14M | 1.41M | 1.08M | 581.00K |
| NormalizedIncome | -21.23M | -21.16M | -26.45M | -41.79M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -22.58M | -20.89M | -28.32M | -41.24M |
| TotalExpenses | 23.51M | 22.48M | 27.53M | 41.83M |
| TotalOperatingIncomeAsReported | -22.18M | -22.16M | -27.25M | -41.59M |
| DilutedAverageShares | 6.34M | 5.24M | 4.58M | 4.02M |
| BasicAverageShares | 6.34M | 5.24M | 4.58M | 4.02M |
| DilutedEPS | -3.56 | -3.99 | -6.24 | -10.24 |
| BasicEPS | -3.56 | -3.99 | -6.24 | -10.24 |
| DilutedNIAvailtoComStockholders | -22.58M | -20.89M | -28.32M | -41.24M |
| NetIncomeCommonStockholders | -22.58M | -20.89M | -28.32M | -41.24M |
| NetIncome | -22.58M | -20.89M | -28.32M | -41.24M |
| MinorityInterests | 667.00K | 456.00K | 566.00K | 132.00K |
| NetIncomeIncludingNoncontrollingInterests | -23.25M | -21.34M | -28.89M | -41.37M |
| NetIncomeContinuousOperations | -23.25M | -21.34M | -28.89M | -41.37M |
| TaxProvision | -5.00K | 0.00 | ||
| PretaxIncome | -23.25M | -21.34M | -28.89M | -41.37M |
| OtherIncomeExpense | -1.35M | 274.00K | -1.87M | 550.00K |
| GainOnSaleOfSecurity | -1.35M | 274.00K | -1.87M | 550.00K |
| NetNonOperatingInterestIncomeExpense | 271.00K | 540.00K | 225.00K | -331.00K |
| TotalOtherFinanceCost | -92.00K | 16.00K | 25.00K | 23.00K |
| InterestExpenseNonOperating | 873.00K | 866.00K | 843.00K | 887.00K |
| InterestIncomeNonOperating | 1.14M | 1.41M | 1.08M | 581.00K |
| OperatingIncome | -22.18M | -22.16M | -27.25M | -41.59M |
| OperatingExpense | 22.83M | 22.48M | 27.52M | 41.83M |
| ResearchAndDevelopment | 12.85M | 12.45M | 15.74M | 24.38M |
| SellingGeneralAndAdministration | 9.98M | 10.03M | 11.78M | 17.45M |
| GeneralAndAdministrativeExpense | 9.98M | 10.03M | 11.78M | 17.45M |
| OtherGandA | 9.98M | 10.03M | 11.78M | 17.45M |
| GrossProfit | 654.00K | 322.00K | 278.00K | 234.00K |
| CostOfRevenue | 682.00K | 4.00K | 9.00K | 0.00 |
| TotalRevenue | 1.34M | 326.00K | 287.00K | 234.00K |
| OperatingRevenue | 1.34M | 326.00K | 287.00K | 234.00K |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 7.89M | 5.41M | 5.16M | 4.06M |
| ShareIssued | 7.89M | 5.41M | 5.16M | 4.06M |
| NetDebt | 21.39M | 17.24M | 18.17M | 11.91M |
| TotalDebt | 34.05M | 29.61M | 29.91M | 28.80M |
| TangibleBookValue | -12.77M | 96.00K | 13.36M | 30.04M |
| InvestedCapital | 20.45M | 24.12M | 36.88M | 51.72M |
| WorkingCapital | -10.23M | 26.65M | 35.79M | 50.92M |
| NetTangibleAssets | -12.77M | 96.00K | 13.36M | 30.04M |
| CapitalLeaseObligations | 6.76M | 5.58M | 6.38M | 7.12M |
| CommonStockEquity | -6.84M | 96.00K | 13.36M | 30.04M |
| TotalCapitalization | -6.84M | 24.12M | 36.88M | 51.72M |
| TotalEquityGrossMinorityInterest | -865.00K | 5.42M | 15.30M | 32.19M |
| MinorityInterest | 5.98M | 5.32M | 1.95M | 2.15M |
| StockholdersEquity | -6.84M | 96.00K | 13.36M | 30.04M |
| RetainedEarnings | -443.06M | -420.47M | -399.58M | -371.26M |
| AdditionalPaidInCapital | 436.21M | 420.57M | 412.94M | 401.30M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 39.55M | 34.11M | 35.50M | 35.88M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 7.22M | 29.66M | 29.88M | 29.05M |
| EmployeeBenefits | 703.00K | 605.00K | 598.00K | 867.00K |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 703.00K | 605.00K | 598.00K | 867.00K |
| NonCurrentDeferredLiabilities | 415.00K | 0.00 | ||
| NonCurrentDeferredTaxesLiabilities | 415.00K | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 6.10M | 29.05M | 29.28M | 28.18M |
| LongTermCapitalLeaseObligation | 6.10M | 5.03M | 5.75M | 6.50M |
| LongTermDebt | 24.03M | 23.53M | 21.68M | 23.85M |
| CurrentLiabilities | 32.33M | 4.45M | 5.62M | 6.83M |
| OtherCurrentLiabilities | 457.00K | |||
| CurrentDeferredLiabilities | 341.00K | 124.00K | 151.00K | 112.00K |
| CurrentDeferredRevenue | 341.00K | 124.00K | 151.00K | 112.00K |
| CurrentDebtAndCapitalLeaseObligation | 27.95M | 559.00K | 627.00K | 619.00K |
| CurrentCapitalLeaseObligation | 659.00K | 559.00K | 627.00K | 619.00K |
| CurrentDebt | 27.29M | |||
| OtherCurrentBorrowings | 27.29M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 859.00K | 702.00K | 873.00K | 1.05M |
| PayablesAndAccruedExpenses | 3.18M | 3.07M | 3.97M | 4.59M |
| CurrentAccruedExpenses | 1.76M | 1.69M | 1.71M | 2.25M |
| Payables | 1.42M | 1.38M | 2.26M | 2.33M |
| OtherPayable | 555.00K | 415.00K | 448.00K | 549.00K |
| AccountsPayable | 866.00K | 964.00K | 1.81M | 1.78M |
| TotalAssets | 38.68M | 39.53M | 50.80M | 68.06M |
| TotalNonCurrentAssets | 16.59M | 8.42M | 9.39M | 10.32M |
| OtherNonCurrentAssets | 1.33M | 704.00K | 628.00K | 648.00K |
| DefinedPensionBenefit | 610.00K | 470.00K | 439.00K | 661.00K |
| NonCurrentPrepaidAssets | 0.00 | 23.27M | ||
| GoodwillAndOtherIntangibleAssets | 5.93M | 0.00 | ||
| OtherIntangibleAssets | 2.79M | |||
| Goodwill | 3.14M | 0.00 | ||
| NetPPE | 8.72M | 7.25M | 8.32M | 9.01M |
| AccumulatedDepreciation | -17.99M | -17.70M | -17.45M | -17.09M |
| GrossPPE | 26.71M | 24.95M | 25.77M | 26.09M |
| Leases | 9.17M | 8.77M | 8.77M | 8.74M |
| OtherProperties | 15.03M | 13.72M | 14.64M | 15.05M |
| MachineryFurnitureEquipment | 2.51M | 2.46M | 2.36M | 2.30M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 22.09M | 31.11M | 41.41M | 57.75M |
| HedgingAssetsCurrent | 103.00K | 8.00K | 0.00 | 1.00K |
| RestrictedCash | 422.00K | 254.00K | 269.00K | 1.01M |
| PrepaidAssets | 235.00K | 222.00K | 442.00K | 403.00K |
| Receivables | 722.00K | 638.00K | 527.00K | 1.32M |
| OtherReceivables | 8.00K | 2.00K | 38.00K | 22.00K |
| TaxesReceivable | 290.00K | 135.00K | 129.00K | 344.00K |
| AccountsReceivable | 424.00K | 501.00K | 360.00K | 955.00K |
| CashCashEquivalentsAndShortTermInvestments | 20.61M | 29.98M | 40.17M | 55.02M |
| OtherShortTermInvestments | 14.72M | 23.20M | 34.81M | 45.24M |
| CashAndCashEquivalents | 5.89M | 6.78M | 5.36M | 9.77M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -19.83M | -18.34M | -23.12M | -36.78M |
| IssuanceOfDebt | 0.00 | 24.45M | ||
| IssuanceOfCapitalStock | 9.58M | 91.00K | 8.02M | 0.00 |
| CapitalExpenditure | -1.62M | -323.00K | -262.00K | -280.00K |
| EndCashPosition | 7.20M | 7.67M | 6.26M | 11.41M |
| BeginningCashPosition | 7.67M | 6.26M | 11.41M | 31.84M |
| EffectOfExchangeRateChanges | 177.00K | 11.00K | -22.00K | -3.21M |
| ChangesInCash | -652.00K | 1.40M | -5.13M | -17.22M |
| FinancingCashFlow | 9.53M | 8.84M | 8.02M | 7.50M |
| CashFlowFromContinuingFinancingActivities | 9.53M | 8.84M | 8.02M | 7.50M |
| NetOtherFinancingCharges | -47.00K | 8.75M | 7.50M | |
| ProceedsFromStockOptionExercised | 0.00 | 364.00K | ||
| NetCommonStockIssuance | 9.58M | 91.00K | 8.02M | 0.00 |
| CommonStockIssuance | 9.58M | 91.00K | 8.02M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 24.45M | ||
| NetLongTermDebtIssuance | 0.00 | 24.45M | ||
| LongTermDebtIssuance | 0.00 | 24.45M | ||
| InvestingCashFlow | 8.03M | 10.58M | 9.70M | 11.78M |
| CashFlowFromContinuingInvestingActivities | 8.03M | 10.58M | 9.70M | 11.78M |
| NetOtherInvestingChanges | 373.00K | -6.89M | ||
| NetInvestmentPurchaseAndSale | 9.27M | 10.91M | 9.96M | 12.06M |
| SaleOfInvestment | 9.27M | 10.91M | 9.96M | 12.06M |
| PurchaseOfInvestment | 0.00 | -10.95M | ||
| NetPPEPurchaseAndSale | -1.62M | -323.00K | -262.00K | -280.00K |
| PurchaseOfPPE | -1.62M | -323.00K | -262.00K | -280.00K |
| OperatingCashFlow | -18.21M | -18.02M | -22.86M | -36.50M |
| CashFlowFromContinuingOperatingActivities | -18.21M | -18.02M | -22.86M | -36.50M |
| ChangeInWorkingCapital | -126.00K | -45.00K | -114.00K | -2.87M |
| ChangeInOtherWorkingCapital | -116.00K | 574.00K | 719.00K | 2.06M |
| ChangeInPayablesAndAccruedExpense | 100.00K | -1.09M | -1.26M | -4.69M |
| ChangeInAccruedExpense | -42.00K | -24.00K | 1.80M | -2.22M |
| ChangeInInterestPayable | 1.85M | -2.17M | 78.00K | |
| ChangeInPayable | 142.00K | -1.06M | -1.26M | -4.69M |
| ChangeInAccountPayable | 142.00K | -1.06M | -22.00K | -758.00K |
| ChangeInPrepaidAssets | 1.00K | -44.00K | 768.00K | 93.00K |
| ChangeInReceivables | -111.00K | 514.00K | -336.00K | -329.00K |
| ChangesInAccountReceivables | -202.00K | 76.00K | ||
| OtherNonCashItems | 3.26M | 497.00K | 1.80M | -2.22M |
| StockBasedCompensation | 2.14M | 2.62M | 3.98M | 8.91M |
| DepreciationAmortizationDepletion | 316.00K | 253.00K | 362.00K | 1.05M |
| DepreciationAndAmortization | 316.00K | 253.00K | 362.00K | 1.05M |
| Depreciation | 316.00K | 253.00K | 362.00K | 1.05M |
| OperatingGainsLosses | -556.00K | 8.00K | ||
| PensionAndEmployeeBenefitExpense | 8.00K | |||
| GainLossOnInvestmentSecurities | -556.00K | |||
| NetIncomeFromContinuingOperations | -23.25M | -21.34M | -28.89M | -41.37M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PLUR
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|